Methylphenidate (MFD) is the drug used for Attention Deficit/Hiperactivity Disorder (ADHD). In the clinic, there is a prevalence of ADHD in patients with epilepsy, being identified as a common comorbidity. The FDA warns against the use of MFD in patients with epilepsy. In this way, it is resolved to investigate in more depth the possible activity of MFD in patients with epilepsy. The objective is to evaluated t...
This study aimed to investigate the in vitro antioxidant activity of the novel anticonvulsant levetiracetam and benzodiazepine clonazepam. To do this, the mice brain homogenates were incubated with levetiracetam (50, 100 or 200 g/ml) or clonazepam (50, 100 or 200 g/ml), and then, submitted to heating at 37°C for 1 h. Ascorbic acid (vitamin C, 200 g/ml) was used as reference antioxidant drug. The markers of o...
Attention-deficit hyperactivity disorder (ADHD) is a prevalent and debilitating disorder diagnosed on the basis in persistent levels of overactivity, inattention and impulsivity. Stimulant drugs have been effective in treating this disorder, and methylphenidate (MPH) is the most widely prescribed therapeutic agent and its use has increased significantly in recent years, however, the consequences of its use are ...
Arthropod venoms are potential sources of neuroactive substances, providing new tools for the design of drugs. The aim of this study was to evaluate the effects of Dinoponera quadriceps venom (DqV) on seizure models in mice induced by pentylenetetrazole (PTZ), pilocarpine, and strychnine. In the PTZ model, intraperitoneal treatment with DqV (0.5 mg/kg) increased the time until the first seizure and the percenta...